Home › Onglyza (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating ...
 

Keywords :   


Onglyza (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating ...

2013-09-02 10:10:35| Biotech - Topix.net

Onglyza Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial AstraZeneca and Bristol-Myers Squibb Company today announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular ... (more)

Tags: primary safety demonstrating achieves

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Panasonic offers Fire TV, Google TV and Powered by TiVo
20.05Eutelsat reports results for the period ended 31 March 2024
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05May/June 2024 Digital Edition of National Hog Farmer now available
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
20.05Valmet Names New Vice President Services, North America
20.05NABC hosts foreign animal disease tabletop exercise
20.05NABC hosts foreign animal disease tabletop exercise
More »